このページの翻訳は実験的なもので、現在開発中です。お待ちしております！

Abbott Laboratories (Pakistan) マネジメント

マネジメント基準チェック /14

現在、CEO に関する十分な情報がありません。

主要情報

最高経営責任者

n/a

報酬総額

CEO給与比率	n/a
CEO在任期間	no data
CEOの所有権	n/a
経営陣の平均在職期間	データなし
取締役会の平均在任期間	4.2yrs

経営陣の近況

Recent updates

CEO（最高経営責任者

Abbott Laboratories (Pakistan) CEOがいない、あるいは彼らに関するデータがない。

取締役

名称	ポジション	在職期間	報酬	所有権
Seema Khan	Executive Director	no data	データなし	データなし
Mohsin Nathani	Independent Director	4.2yrs	データなし	0.015% PKR 11.4m
Ehsan Malik	Independent Non-Executive Chairman	10.3yrs	データなし	0.0071% PKR 5.3m
Muhammad Latif Rana	Non-Executive Director	4.2yrs	データなし	0% PKR 0
Ayla Majid	Independent Director	4.2yrs	データなし	0.00051% PKR 379.4k
Celestino Dos Anjos	Non-Executive Director	1.9yrs	データなし	データなし

4.2yrs

平均在職期間

経験豊富なボード: ABOTの取締役会は経験豊富であると考えられます ( 4.1年の平均在任期間)。

Abbott Laboratories (Pakistan) マネジメント

マネジメント基準チェック /14

主要情報

経営陣の近況

Less than half of directors are independent

Less than half of directors are independent

Abbott Laboratories Announces Board Changes

Less than half of directors are independent

Recent updates

First quarter 2024 earnings released: EPS: PK₨15.51 (vs PK₨2.24 loss in 1Q 2023)

Full year 2023 earnings released: EPS: PK₨2.67 (vs PK₨30.69 in FY 2022)

Third quarter 2023 earnings released: EPS: PK₨0.07 (vs PK₨8.02 in 3Q 2022)

Second quarter 2023 earnings released: PK₨5.93 loss per share (vs PK₨3.45 profit in 2Q 2022)

Less than half of directors are independent

Third quarter 2022 earnings released: EPS: PK₨8.02 (vs PK₨12.36 in 3Q 2021)

Second quarter 2022 earnings released: EPS: PK₨3.45 (vs PK₨18.79 in 2Q 2021)

Less than half of directors are independent

Abbott Laboratories Announces Board Changes

Less than half of directors are independent

Upcoming dividend of PK₨20.00 per share

Third quarter 2021 earnings released: EPS PK₨12.36 (vs PK₨10.07 in 3Q 2020)

Upcoming dividend of PK₨20.00 per share

Second quarter 2021 earnings released: EPS PK₨18.79 (vs PK₨12.85 in 2Q 2020)

First quarter 2021 earnings released: EPS PK₨14.73 (vs PK₨8.81 in 1Q 2020)

Upcoming dividend of PK₨25.00 per share

Full year 2020 earnings released: EPS PK₨46.33 (vs PK₨13.28 in FY 2019)

Full year 2020 earnings released: EPS PK₨46.33 (vs PK₨13.28 in FY 2019)

Third quarter earnings released

New 90-day high: PK₨778

New 90-day high - PK₨773

First half earnings released

New 90-day high - PK₨699

CEO（最高経営責任者

取締役

平均在職期間

Abbott Laboratories (Pakistan) マネジメント

マネジメント 基準チェック /14

主要情報

経営陣の近況

Less than half of directors are independent

Less than half of directors are independent

Abbott Laboratories Announces Board Changes

Less than half of directors are independent

Recent updates

First quarter 2024 earnings released: EPS: PK₨15.51 (vs PK₨2.24 loss in 1Q 2023)

Full year 2023 earnings released: EPS: PK₨2.67 (vs PK₨30.69 in FY 2022)

Third quarter 2023 earnings released: EPS: PK₨0.07 (vs PK₨8.02 in 3Q 2022)

Second quarter 2023 earnings released: PK₨5.93 loss per share (vs PK₨3.45 profit in 2Q 2022)

Less than half of directors are independent

Third quarter 2022 earnings released: EPS: PK₨8.02 (vs PK₨12.36 in 3Q 2021)

Second quarter 2022 earnings released: EPS: PK₨3.45 (vs PK₨18.79 in 2Q 2021)

Less than half of directors are independent

Abbott Laboratories Announces Board Changes

Less than half of directors are independent

Upcoming dividend of PK₨20.00 per share

Third quarter 2021 earnings released: EPS PK₨12.36 (vs PK₨10.07 in 3Q 2020)

Upcoming dividend of PK₨20.00 per share

Second quarter 2021 earnings released: EPS PK₨18.79 (vs PK₨12.85 in 2Q 2020)

First quarter 2021 earnings released: EPS PK₨14.73 (vs PK₨8.81 in 1Q 2020)

Upcoming dividend of PK₨25.00 per share

Full year 2020 earnings released: EPS PK₨46.33 (vs PK₨13.28 in FY 2019)

Full year 2020 earnings released: EPS PK₨46.33 (vs PK₨13.28 in FY 2019)

Third quarter earnings released

New 90-day high: PK₨778

New 90-day high - PK₨773

First half earnings released

New 90-day high - PK₨699

CEO（最高経営責任者

取締役

平均在職期間

マネジメント基準チェック /14